And the results of target-based screening by Subpathway-GM indicated that ALDH1A1 was the potential target for Silybin in the treatment of prostate cancer and it could regulate the synthesis of all trans-retinoic acid as well as 9-cis-Retinoate which could inhibit the cancer cell-stimulated proliferation and differentiation of the pro-tumoral macrophages and to act as a tumor suppressor gene in the prostate cancer (Jiang et al., 2006; Tsagozis et al., 2014). The gene discussed is ALDH1A1; the disease is prostate carcinoma.